Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 25Cyclophosphamide 23venetoclax 16Methotrexate 15Daunorubicin 14Dexamethasone 13Vincristine 11Etoposide 11Azacitidine 10Idarubicin 9Decitabine 9Busulfan 9fludarabine 8Radiotherapy 8Prednisone 8Stem Cell Transplantation 7Mercaptopurine 7Doxorubicin 7Asparaginase 7pegaspargase 6fludarabine phosphate 6blinatumomab 6Granulocyte Colony-Stimulating Factor 6Gemtuzumab 6Filgrastim 6Thiotepa 5Methylprednisolone 5Dasatinib 5Whole-Body Irradiation 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × orelabrutinib × Other hematologic neoplasm × Clear all
NCT06378138 2025-11-21

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2/3 Recruiting
226 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡